Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q1 FY26 results · Apr–Jun 2025
Tatva Chintan Pharma Chem reported revenue from operations of ₹116.86 crore (up 10.8% from Q1 FY25) and net profit of ₹6.65 crore (up 27.7% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 116.86 | 105.46 | +10.8% | 107.86 | +8.3% |
| Other income | 1.16 | 1.17 | −1.5% | 0.72 | +60.0% |
| Total income | 118.02 | 106.64 | +10.7% | 108.59 | +8.7% |
| Profit before tax | 9.10 | 6.81 | +33.7% | 2.03 | +349.0% |
| Net profit for the period | 6.65 | 5.21 | +27.7% | 1.03 | +545.7% |
| EPS, basic (₹) | 2.84 | 2.23 | +27.4% | 0.44 | +545.5% |
| Net margin (%) | 5.7 | 4.9 | 1.0 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 109.18 | 93.81 | +16.4% | 107.65 | +1.4% |
| Other income | 1.37 | 1.42 | −3.6% | 1.29 | +5.7% |
| Total income | 110.55 | 95.23 | +16.1% | 108.94 | +1.5% |
| Profit before tax | 7.05 | 2.14 | +230.1% | 1.55 | +353.9% |
| Net profit for the period | 5.13 | 1.51 | +240.4% | 1.09 | +368.8% |
| EPS, basic (₹) | 2.19 | 0.64 | +242.2% | 0.47 | +366.0% |
| Net margin (%) | 4.7 | 1.6 | 1.0 |
Consolidated
- Filed with BSE
- 24 Jul 2025, 19:59 IST
- Board meeting
- 24 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jul 2025, 19:59 IST
- Board meeting
- 24 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE